ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $291,000 | -7.0% | 6,601 | +4.1% | 0.00% | – |
| Q1 2021 | $313,000 | +17.2% | 6,343 | 0.0% | 0.00% | – |
| Q4 2020 | $267,000 | -9.5% | 6,343 | -1.6% | 0.00% | – |
| Q3 2020 | $295,000 | -35.6% | 6,443 | -29.4% | 0.00% | – |
| Q2 2020 | $458,000 | -26.5% | 9,129 | -24.7% | 0.00% | -100.0% |
| Q1 2020 | $623,000 | -16.6% | 12,121 | +0.2% | 0.00% | 0.0% |
| Q4 2019 | $747,000 | +2.9% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $726,000 | -28.8% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,020,000 | -50.0% | 12,092 | -50.7% | 0.00% | 0.0% |
| Q1 2019 | $2,039,000 | +135.7% | 24,503 | +100.6% | 0.00% | 0.0% |
| Q4 2018 | $865,000 | -17.1% | 12,214 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,044,000 | -38.7% | 12,214 | -16.8% | 0.00% | -50.0% |
| Q2 2018 | $1,702,000 | +6.8% | 14,683 | -25.5% | 0.00% | 0.0% |
| Q1 2018 | $1,594,000 | – | 19,697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |